TARGETING NUCLEAR BILE ACID RECEPTOR FXR IN PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS
- 3 Years 2008/2011
- 205.700€ Total Award
Progressive Familial Intrahepatic Cholestasis (PFIC) includes 3 diseases caused by mutations in genes responsible for bile formation, characterized by early onset, progressive behavior and severe prognosis: manifested in the first years of life, they often lead to liver failure before adulthood. Clinical presentation combines failure to thrive with pruritus and jaundice. These conditions are cause by mutations in genes responsible for proper bile formation and flow. Homozygous mutations in the “pump” for bile acids located on the hepatocyte plasma membrane facing the biliary canaliculus (bile acid export pump: ATP Binding Cassette (ABC)-B11) is the cause PFIC type 2. PFIC type 3 is caused by mutations in the phospholipid transporter (ABC-B4). While liver transplantation is the only curative therapy at the moment, new hope comes from recent insights into nuclear receptor physiology in the gut-liver axis. Proper bile formation, in fact, relies on the coordinate activity of liver and intestine, and its modulation by dietary and hormonal signals. Nuclear receptors achieve these functions. Nuclear receptors are the gatekeepers of lipid welfare in the body: after activation by specific ligands, nuclear receptor prime the activation of multiple genes (increased transcription) leading to accurate, synchronized and coherent functional responses. In particular, FXR is the bile acid nuclear sensor, orchestrating bile acid homeostasis through liver and intestine (enterohepatic circulation). In the hepatocyte FXR directly up-regulates biliary bile acid and phospholipid secretion. In the enterocyte FXR induces the expression of the hormone Fibroblast Growth Factor (FGF)-15 which inhibits hepatic bile acid synthesis through cholesterol 7a-hydroxylase CYP7A1 suppression. Intestinal FXR activation is mandatory for the inhibition of bile acid synthesis. Since bile acid are cytotoxic-detergent molecules, strategies aiming at reducing bile acid levels are anticipated to be beneficial.
Scientific Publications
- 2011 WILEY INTERDISCIPLINARY REVIEWS-SYSTEMS BIOLOGY AND MEDICINE
Lipid-sensing nuclear receptors in the pathophysiology and treatment of the metabolic syndrome
- 2012 GASTROENTEROLOGY
Selective Activation of Nuclear Bile Acid Receptor FXR in the Intestine Protects Mice Against Cholestasis
- 2011 CELL CYCLE
Bax is necessary for PGC1 alpha pro-apoptotic effect in colorectal cancer cells
- 2011 BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Proteomics for the discovery of nuclear bile acid receptor FXR targets
- 2011 GUT
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease
- 2010 HEPATOLOGY
Down-Regulation of the LXR Transcriptome Provides the Requisite Cholesterol Levels to Proliferating Hepatocytes
- 2009 FRONTIERS IN BIOSCIENCE
Master regulation of bile acid and xenobiotic metabolism via the FXR, PXR and CAR trio
- 2011 TRENDS IN MOLECULAR MEDICINE
Bile acids and colon cancer: Solving the puzzle with nuclear receptors
- 2010 CELL METABOLISM
Intestinal Specific LXR Activation Stimulates Reverse Cholesterol Transport and Protects from Atherosclerosis
- 2011 PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AME
Peroxisome proliferator-activated receptor-gamma coactivator 1-alpha (PGC1 alpha) is a metabolic regulator of intestinal epithelial cell fate
- 2009 JOURNAL OF MEDICINAL CHEMISTRY
Synthesis and Biological Evaluation of 2-Heteroarylthioalkanoic Acid Analogues of Clofibric Acid as Peroxisome Proliferator-Activated Receptor alpha Agonists